# Esophageal Cancer

Esophageal cancer management hinges on histology, locoregional resectability, physiologic operability, and metastatic staging. Coordinate endoscopic diagnosis, staging, nutrition, and multidisciplinary selection of surgery-based, definitive chemoradiation, systemic, or symptom-directed treatment early.

**Clinical question:** How should physicians stage and select multimodality treatment for localized or advanced esophageal cancer?

Updated: 2026-08-24T16:58:45.801121+00:00

## What matters in practice
- Separate esophageal squamous cell carcinoma from adenocarcinoma and establish locoregional versus metastatic disease before choosing surgery-based or nonsurgical treatment; ESMO provides recommendations spanning diagnosis, staging, and management. [23][24]
- For localized, medically operable disease, esophagectomy is a treatment choice within multidisciplinary care; definitive chemoradiotherapy is the principal curative-intent alternative for patients who are not surgical candidates or decline surgery. [15]
- For advanced esophageal squamous cell carcinoma, platinum-based chemotherapy is a standard first-line backbone, and chemotherapy plus immunotherapy is described as a standard strategy for advanced disease. [11][17]
- In advanced symptomatic disease, select palliation according to dysphagia burden, performance status, comorbidities, anatomy, and patient goals; endoscopic procedures, radiation, systemic treatment, and combinations may be appropriate. [18]

## Confirm histology and define the treatment-intent branch

Move rapidly from tissue diagnosis to multidisciplinary staging and physiologic assessment.

At diagnosis, assign histology as esophageal squamous cell carcinoma (ESCC) or esophageal adenocarcinoma (EAC), the two major esophageal cancer subtypes. This distinction is clinically consequential because ESCC more often enters a definitive chemoradiotherapy pathway when surgery is unsuitable, whereas resection-based multimodality treatment is a central option for operable localized disease. [10][15][23]

Before committing to curative-intent local treatment, determine whether disease is localized, locally advanced but potentially treatable with multimodality therapy, or metastatic. ESMO guidance explicitly addresses clinical and pathologic diagnosis, staging, and management, supporting a coordinated staging decision rather than sequential, uncoordinated referrals. [23][24]

At the first oncology and surgical assessment, document dysphagia severity, oral intake, weight trajectory, performance status, cardiopulmonary reserve, and the patient’s willingness to undergo esophagectomy. These variables determine whether the next step is a surgery-based strategy, definitive chemoradiotherapy, systemic treatment, or immediate symptom palliation. [15][18]
- Escalate urgently when dysphagia prevents adequate hydration or nutrition, when aspiration is suspected, or when a tracheoesophageal fistula is present; these situations require prompt symptom-directed intervention while staging proceeds. [18]
- Use multidisciplinary review before treatment selection because surgery, radiation therapy, systemic therapy, endoscopic treatment, and combinations have distinct roles across localized and advanced disease. [15][18][23]

*Treatment-intent branches after diagnostic and staging assessment. [15][17][18][23]*

| Clinical branch | Primary next decision | Management direction |
| --- | --- | --- |
| Localized disease; medically operable and accepts surgery | Assess candidacy for a surgery-based multimodality plan | Esophagectomy is a treatment option within multidisciplinary management. [15] |
| Localized or locally advanced disease; not a surgical candidate or declines surgery | Assess suitability for curative-intent definitive chemoradiotherapy | Definitive chemoradiotherapy is the principal nonsurgical option described for this group. [15] |
| Advanced ESCC requiring first-line systemic treatment | Select systemic regimen and assess immunotherapy suitability | Platinum-based chemotherapy is a standard backbone; chemotherapy plus immunotherapy is described as a standard strategy for advanced disease. [11][17] |
| Advanced disease with clinically dominant dysphagia or fistula | Prioritize restoration of swallowing and symptom control alongside oncologic planning | Use endoscopic procedures, radiation therapy, systemic therapy, surgery in selected circumstances, or combinations according to anatomy and goals. [18] |

## Select surgery-based therapy versus definitive chemoradiotherapy

Operability and patient preference are treatment determinants, not afterthoughts.

For a patient with localized disease who is medically fit and willing to undergo surgery, discuss esophagectomy in a multidisciplinary setting. Surgical candidacy must incorporate disease extent, technical resectability, cardiopulmonary risk, nutritional condition, and anticipated postoperative recovery rather than tumor stage alone. [15][23]

For a patient with locally advanced disease who cannot undergo esophagectomy because of medical risk or who declines surgery, use definitive chemoradiotherapy as the established nonsurgical treatment pathway. This branch should be framed as a planned definitive strategy, not as incomplete surgical care. [15]

Histology should remain visible in the treatment discussion. Chemoradiation is described as a reasonable primary alternative to esophagectomy in ESCC and is also reported to provide palliation and potential long-term disease control in adenocarcinoma; individualized multidisciplinary selection is therefore required rather than a single histology-blind rule. [18]
- Obtain early nutrition input when dysphagia or weight loss threatens completion of multimodality treatment; inadequate intake can alter treatment tolerance and sequencing. [18]
- Reassess swallowing during chemoradiotherapy because local interventions may be required when dysphagia remains the immediate clinical problem. [18]
- Do not defer a decision about definitive local treatment while repeatedly pursuing palliative endoscopic measures in a patient who remains potentially curable; establish treatment intent first. [15][18][23]

### When nonsurgical definitive treatment is preferred

Definitive chemoradiotherapy is the best-described option when esophagectomy is contraindicated or declined. The decision should be recorded explicitly after assessment of surgical risk, performance status, tumor characteristics, and patient goals, with continued surveillance for persistent or recurrent local symptoms. [15]
- Use endoscopic or radiation-based palliation selectively if dysphagia requires more immediate relief than systemic treatment can provide. [18]

*Decision factors for localized esophageal cancer treatment intent. [15][18][23]*

| Finding | Interpretation | Next action |
| --- | --- | --- |
| Medically operable patient with localized disease who accepts surgery | A surgery-based multimodality approach is feasible | Refer for multidisciplinary planning that includes esophagectomy assessment. [15][23] |
| Patient is medically inoperable | Operative morbidity is unacceptable | Plan definitive chemoradiotherapy when clinically appropriate. [15] |
| Patient declines esophagectomy | Patient preference excludes surgical treatment | Offer definitive chemoradiotherapy rather than abandoning curative-intent local therapy solely because surgery is declined. [15] |
| Persistent clinically limiting dysphagia | Symptom control may require a parallel intervention | Choose radiation, endoscopic intervention, systemic treatment, or a combination based on disease setting and goals. [18] |

## Use systemic therapy for advanced disease and match local measures to symptoms

For advanced disease, separate disease control from urgent relief of obstructive symptoms.

For treatment-naive advanced ESCC, platinum-based chemotherapy is a standard first-line treatment backbone. Contemporary expert consensus further identifies chemotherapy combined with immunotherapy as a standard strategy for advanced esophageal cancer, making systemic-treatment selection a central first-line decision when curative local treatment is not feasible. [11][17]

Do not use systemic therapy choice as a substitute for managing dangerous or disabling local complications. Advanced esophageal cancer can require concurrent palliative endoscopic procedures, radiation therapy, chemotherapy, chemoradiation, or selected surgical interventions; choose among these based on dysphagia severity, fistula, performance status, comorbidity, and patient priorities. [18]

Communicate prognosis and treatment goals directly. Historical reports note that survival in advanced ESCC can be limited, with median overall survival near 11 months in cited literature, reinforcing the need to define whether the near-term goal is swallowing, symptom relief, disease control, or all three. [8]
- For advanced ESCC, consider a platinum-containing systemic backbone and evaluate whether chemotherapy plus immunotherapy is appropriate in the planned regimen. [11][17]
- If dysphagia is the dominant problem, coordinate systemic treatment with endoscopic or radiation-based palliation rather than waiting for systemic response alone. [18]
- If tracheoesophageal fistula is present, prioritize fistula-directed palliation; radiation therapy or bypass surgery are described as interventions that may prolong survival. [18]

*Symptom-directed options in advanced esophageal cancer. [18]*

| Clinical problem | Interventions described | Decision principle |
| --- | --- | --- |
| Dysphagia from obstructing tumor | Endoscopic procedures, external-beam or intraluminal radiation, chemotherapy, chemoradiation, and combinations. [18] | Select according to urgency of relief, extent of disease, performance status, comorbidity, and patient preference. [18] |
| Locally advanced disease needing palliation and disease control | Chemoradiation. [18] | Chemoradiation provides better survival than radiation alone in the cited palliative review and may palliate dysphagia. [18] |
| Tracheoesophageal fistula | Radiation therapy or bypass surgery; other palliative approaches may be considered. [18] | Prioritize fistula control and aspiration risk; radiation or bypass surgery are described as survival-prolonging options. [18] |

## Treat dysphagia as an active oncologic problem

Swallowing impairment can determine treatment feasibility before tumor-directed therapy can act.

In a patient with advanced disease, dysphagia palliation should be individualized rather than automatically procedural. Available approaches include radiation therapy, chemotherapy, chemoradiation, endoscopic procedures, surgery, and combinations; the appropriate choice depends on the patient’s disease distribution, coexisting illness, performance status, and preferences. [18]

Chemoradiation has been reported to provide dysphagia palliation in up to 90% of patients in the cited palliative review and to improve survival compared with radiation alone. This supports considering chemoradiation when a patient can tolerate combined therapy and needs both local symptom control and antitumor treatment. [18]

Use nutrition and hydration status as a treatment-readiness checkpoint. When oral intake is inadequate because of dysphagia, coordinate nutrition intervention with the oncology and endoscopy teams so that symptom management does not delay the selected definitive or systemic treatment plan. [18]
- Reassess dysphagia after each major treatment transition because progression, treatment-related inflammation, or incomplete local response can change the appropriate palliative modality. [18]
- For patients with major comorbidity or poor performance status, choose the least burdensome intervention capable of achieving the patient’s stated swallowing and symptom goals. [18]

*Practical sequencing for dysphagia-focused care. [18]*

| Priority | Action | Rationale |
| --- | --- | --- |
| Immediate oral-intake threat | Assess hydration, nutrition, aspiration risk, and fistula; arrange prompt symptom-directed intervention. [18] | Obstruction and fistula can require local palliation before longer-latency systemic benefit. [18] |
| Potentially curable local disease | Align dysphagia management with the selected surgery-based or definitive chemoradiotherapy pathway. [15][18] | Avoid symptom procedures that derail definitive treatment planning without a clear indication. [15][18] |
| Metastatic or noncurable disease | Combine systemic disease control with an endoscopic or radiation approach when swallowing relief is needed. [17][18] | Advanced-disease care should address both tumor control and quality of life. [18] |

## Use surveillance to identify clinically actionable recurrence or treatment failure

Follow-up should be structured around symptoms, treatment sequelae, and salvage opportunities.

After definitive local therapy, investigate new or progressive dysphagia, weight loss, aspiration symptoms, or decline in oral intake promptly because these findings can signal local persistence, recurrence, stricture, fistula, or treatment-related complications requiring endoscopic, radiotherapeutic, surgical, or systemic reassessment. [18]

Circulating tumor DNA is being studied for risk stratification and residual-disease detection after neoadjuvant treatment in stage I-II and other operable esophageal cancer settings. It is prognostically promising but should not replace established staging, clinical assessment, or treatment decisions outside a validated management pathway. [6][12]

Maintain histology-specific and disease-setting-specific review at recurrence. Advanced ESCC has a systemic-therapy evidence base incorporating platinum chemotherapy and chemoimmunotherapy, while recurrent local symptoms may independently warrant a local palliative procedure. [11][17][18]
- Use new dysphagia or fistula symptoms as triggers for expedited multidisciplinary reassessment rather than routine follow-up alone. [18]
- Treat ctDNA as an emerging risk-assessment tool rather than a stand-alone determinant of escalation or de-escalation. [6][12]

*Post-treatment reassessment triggers. [6][12][18]*

| Trigger | Clinical concern | Next step |
| --- | --- | --- |
| Recurrent or worsening dysphagia | Local recurrence, persistent obstruction, treatment-related narrowing, or progression. [18] | Expedite clinical, endoscopic, and multidisciplinary reassessment directed by the suspected complication. [18] |
| New aspiration symptoms or suspected tracheoesophageal fistula | Potential airway contamination and major local complication. [18] | Urgently evaluate for fistula and select fistula-directed palliation. [18] |
| Detectable ctDNA in an investigational perioperative surveillance context | Possible residual disease or increased recurrence risk. [6][12] | Interpret within validated protocols or multidisciplinary discussion; do not substitute it for standard clinical assessment. [6][12] |

## References
1. Curriculum Vitae: Jaffer A. Ajani, MD — www.fda.gov — https://www.fda.gov/media/130602/download
2. Jonathan D. Cheng, MD — www.fda.gov — https://www.fda.gov/media/132448/download
3. Pamela L. Kunz Curriculum Vitae — www.fda.gov — https://www.fda.gov/media/170270/download
4. Device Registration and Listing Module System — www.access.fda.gov — https://www.access.fda.gov/drlm/drlm.htm
5. Evaluation of Clinical and Safety Outcomes of Neoadjuvant ... — jamanetwork.com — https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2798101
6. Preoperative Circulating Tumor DNA Detection and Risk ... — jamanetwork.com — https://jamanetwork.com/journals/jamasurgery/fullarticle/2845372
7. Esophageal Disease — jamanetwork.com — https://jamanetwork.com/collections/5637/esophageal-disease
8. Immunotherapy for Advanced Esophageal Squamous Cell ... — jamanetwork.com — https://jamanetwork.com/journals/jamaoncology/fullarticle/2784221
9. National Institute for Health and Care Excellence (NICE ... - Gut — gut.bmj.com — https://gut.bmj.com/content/73/6/897
10. Efficacy among neoadjuvant therapy for resectable ... — www.cell.com — https://www.cell.com/iscience/fulltext/S2589-0042(26)00992-2
11. Toripalimab plus chemotherapy in treatment-naïve ... — www.cell.com — https://www.cell.com/cancer-cell/fulltext/S1535-6108(22)00059-9
12. ctDNA detects residual disease after neoadjuvant ... — www.cell.com — https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25)00407-0
13. Neoadjuvant immunochemoradiotherapy with nivolumab, paclitaxel, and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma | British Journal of Cancer — www.nature.com — https://www.nature.com/articles/s41416-026-03349-6
14. Biomarker-targeted therapies for advanced-stage ... — www.cell.com — https://www.cell.com/heliyon/fulltext/S2405-8440(26)00591-8
15. Multi-disciplinary management of esophageal carcinoma — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1040842824000581
16. Thoracic: Esophageal Cancer The impact of neoadjuvant ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2666273623000906
17. Expert consensus on radiotherapy combined with ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2666555724000054
18. Palliative treatment of esophageal cancer - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1053429605800682
19. Carcinoma of Esophagus - Sung - 2025 — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/jgh.16990
20. Screening for Esophageal Cancer - Phan - 2026 — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/jgh.70196
21. Current status and perspectives of esophageal cancer: a ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/cac2.12645
22. (PDF) Epidemiology of esophageal cancer in 2020 and ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14745
23. ESMO Clinical Practice Guideline: Oesophageal Cancer — www.esmo.org — https://www.esmo.org/guidelines/esmo-clinical-practice-guideline-oesophageal-cancer
24. ESMO Clinical Practice Guidelines: Gastrointestinal Cancers — www.esmo.org — https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-gastrointestinal-cancers

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.